Economic burden of relapsed or refractory relapse multiple myeloma

Author : Gihan Hamdy Elsisi , Khulood Mahmoud , Mohamed El-Naggar

Objective:

The economic burden of transplant-eligible multiple myeloma patients in Egypt has yet to be determined. The current study sought to assess the economic burden of refractory/relapsed multiple myeloma (RRMM) patients who are transplant candidates over a one-year period.

Methods:

A dynamic model will be created to estimate the financial costs of implementing triplet therapy with daratumumab, dexamethasone, and bortezomib in RRMM. The model's structure reflects the disease's natural history, current practises, and published studies in this area. The model population will enter the model and progress through three stages of health (progression free, progressed, and death).

The costs of adverse events associated with drugs used to treat multiple myeloma will be estimated based on the frequency of each event and the pharmacy costs associated with their management.



Results:

The total cost of the bortezomib, dexamethasone, and daratumumab regimen was estimated to be 157340 EGP per patient. The variable parameters had no effect on the final results, according to a one-way sensitivity analysis.



Conclusions:

The current study concludes that the economic burden of RRMM patients who are transplant eligible is burdensome and costly from the patient's perspective. This study contributes to better health outcomes in Egypt by informing decisions about the allocation of health-care system resources.

References: 1-Gihan Hamdy Elsisi , João L. Carapinha, et al. A budget impact analysis of lenalidomide in multiple myeloma Egyptian patient. J Med Econ. 2020 Oct;23(10):1168-1175

2-Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P; CASTOR Investigators. Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2016 Aug 25;375(8):754-66. doi: 10.1056/NEJMoa1606038. PMID: 27557302.